December 7, 2015 J&J leukemia drug cuts death risk vs. chemo in new patients, study finds Johnson & Johnson's and AbbVie's cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study, paving the way for an expanded approval of the medicine.
December 4, 2015 Risk of death nearly doubled for Vietnam veterans with PTSD Higher than average death rates among Vietnam War veterans with post-traumatic stress disorder (PTSD) suggest that combat trauma may still be affecting veterans' health even decades after the war, according to a new study.
December 1, 2015 Cancer patients may benefit from mindfulness-based therapy Mindfulness-based therapy may help ease anxiety and depression in some patients with cancer, a small research review suggests.
November 30, 2015 FDA approves new Bristol-Myers treatment for multiple myeloma The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer.
November 25, 2015 Childhood cancer survivors may face physical, mental health issues Childhood cancer survivors may face a higher than average risk of hospitalizations and cognitive challenges later in life, two recent studies in JAMA Oncology suggest.
November 23, 2015 FDA approves Takeda drug for blood cancer multiple myeloma The U.S. Food and Drug Administration on Friday approved a third drug to treat multiple myeloma, a type of blood cancer.
November 19, 2015 Servier and Pfizer get rights to Cellectis cancer cell therapy U.S. drugmaker Pfizer and France's Servier have snapped up rights to a promising cell therapy developed by French biotech firm Cellectis to fight blood cancers.
